Gerresheimer cuts its 2025 revenue outlook for second time

German packaging and medical equipment maker Gerresheimer (GXIG.DE) has cut its 2025 revenue growth outlook for the second time to a range of 0% to 2%, citing continued weak demand in the cosmetic and oral liquids markets, which significantly impacted its moulded glass business. This revision follows activist investor pressure for strategic changes, including a potential divestment of the underperforming moulded glass unit. While the company confirmed its adjusted EBITDA margin outlook of around 20%, it also lowered its mid-term revenue growth guidance to 6-9%.

Analysis

Gerresheimer has issued its second downward revision for its 2025 revenue guidance, now forecasting growth between 0% and 2%, reflecting persistent and significant weakness in its cosmetic and oral liquids-related businesses. This underperformance is concentrated in the packaging glass division, which, according to J.P. Morgan analysts, is actively eroding the company's overall growth, margins, and returns. The weakness in this segment stands in stark contrast to the strong demand observed in the drug delivery systems business, highlighting a critical performance divergence between the company's core units. This situation has intensified pressure from activist investor Asset Value Investor, which, along with other top shareholders, is advocating for a strategic divestment of the struggling moulded glass business. While management has maintained its adjusted EBITDA margin forecast of around 20% by banking on a stronger second half, it has also lowered its mid-term revenue growth outlook to 6-9% from 8-10%, signaling that the current challenges are impacting long-term strategy and forcing a revision of investment plans to prioritize cash flow.

Key Decisions for Investors

• Investors should closely scrutinize management's response to activist pressure for the divestment of the underperforming moulded glass business, as its continued drag on performance presents a significant risk to the consolidated top-line.
• The dual downgrade of both near-term and mid-term revenue guidance necessitates a recalibration of valuation models, as the company's growth trajectory is now officially lower than previously communicated.
• Monitor for any signs of recovery in the cosmetic and oral liquids end-markets, as the reiterated EBITDA margin guidance appears heavily dependent on a second-half rebound that may not materialize.